| Estrogen signaling in endometrial cancer: a key oncogenic pathway with several open questions AC Rodriguez, Z Blanchard, KA Maurer, J Gertz Hormones and Cancer 10, 51-63, 2019 | 229 | 2019 |
| BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers Z Blanchard, BT Paul, B Craft, WM ElShamy Breast Cancer Research 17, 1-18, 2015 | 55 | 2015 |
| Estrogen receptor alpha mutations in breast cancer cells cause gene expression changes through constant activity and secondary effects S Arnesen, Z Blanchard, MM Williams, KC Berrett, Z Li, S Oesterreich, ... Cancer research 81 (3), 539-551, 2021 | 43 | 2021 |
| BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin BT Paul, Z Blanchard, M Ridgway, WM ElShamy Oncogene 34 (23), 3036-3052, 2015 | 35 | 2015 |
| Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer Z Blanchard, JM Vahrenkamp, KC Berrett, S Arnesen, J Gertz Genome Research 29 (9), 1429-1441, 2019 | 34 | 2019 |
| Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative Z Blanchard, N Mullins, P Ellipeddi, JM Lage, S McKinney, R El-Etriby, ... PloS one 9 (4), e95663, 2014 | 30 | 2014 |
| Geminin overexpression induces mammary tumors via suppressing cytokinesis Z Blanchard, R Malik, N Mullins, C Maric, H Luk, D Horio, B Hernandez, ... Oncotarget 2 (12), 1011, 2011 | 24 | 2011 |
| BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells Y Shimizu, N Mullins, Z Blanchard, WM ElShamy Oncotarget 3 (3), 299, 2012 | 17 | 2012 |
| Estrogen receptor alpha mutations regulate gene expression and cell growth in breast cancer through microRNAs S Arnesen, JT Polaski, Z Blanchard, KS Osborne, AL Welm, ... NAR cancer 5 (2), zcad027, 2023 | 3 | 2023 |
| Characterization of HCI-EC-23 a novel estrogen-and progesterone-responsive endometrial cancer cell line CM Rush, Z Blanchard, JT Polaski, KS Osborne, K Osby, JM Vahrenkamp, ... Scientific reports 12 (1), 19731, 2022 | 3 | 2022 |
| Estrogen-independent molecular actions of mutant estrogen receptor alpha in endometrial cancer Z Blanchard, JM Vahrenkamp, KC Berrett, S Arnesen, J Gertz BioRxiv, 369165, 2018 | 3 | 2018 |
| Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer Z Blanchard, CM Rush, S Arnesen, JM Vahrenkamp, AC Rodriguez, ... Molecular Cancer Research 21 (10), 1023-1036, 2023 | 2 | 2023 |
| Characterization of a novel estrogen-and progesterone-responsive endometrial cancer cell line: HCI-EC-23 CM Rush, Z Blanchard, JT Polaski, KS Osborne, K Osby, JM Vahrenkamp, ... bioRxiv, 2022.08. 25.505203, 2022 | | 2022 |
| Characterization of molecular, phenotypic, and drug sensitivity changes due to estrogen receptor alpha mutations in endometrial cancer. Z Blanchard, JM Vahrenkamp, S Arnesen, KC Berrett, J Gertz CLINICAL CANCER RESEARCH 27 (3), 2021 | | 2021 |
| Abstract PO012: Characterization of molecular, phenotypic, and drug sensitivity changes due to estrogen receptor alpha mutations in endometrial cancer Z Blanchard, JM Vahrenkamp, S Arnesen, KC Berrett, J Gertz Clinical Cancer Research 27 (3_Supplement), PO012-PO012, 2021 | | 2021 |
| Abstract P6-04-13: Preclinical and clinical analyses of estrogen receptor alpha mutant metastatic breast cancer JK Richer, MM Williams, NS Spoelstra, S Arnesen, JL Christenson, ... Cancer Research 80 (4_Supplement), P6-04-13-P6-04-13, 2020 | | 2020 |
| Abstract AS30: BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin BT Paul, Z Blanchard, M Ridgway, WM ElShamy Clinical Cancer Research 21 (16_Supplement), AS30-AS30, 2015 | | 2015 |
Jason GertzAssistant Professor, University of Utah School of Medicine在 hci.utah.edu 的电子邮件经过验证
